Richard Gonzalez Wiki – Richard Gonzalez Biography
Richard Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 47,000 people worldwide and markets medicines in more than 175 countries.
Prior to AbbVie’s separation from Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. He served as President and Chief Operating Officer of Abbott before briefly retiring in 2007. He also held various senior leadership positions in Abbott’s medical products businesses, including President and Chief Operating Officer of the Medical Products Group; Senior Vice President and President of the former Hospital Products Division; Vice President and President of the Health Systems Division; and Divisional Vice President and General Manager for Diagnostics Operations in the United States and Canada.
Mr. Gonzalez has been a long-standing leader in the greater Chicago community where he is a member of the Commercial Club of Chicago and represents AbbVie on their Civic Committee. He is also a member of the Business Roundtable, which is the only national organization representing exclusively CEOs of America’s leading companies.
Beyond that controversy, Gonzalez has kept himself focused on his work, with little known about his personal life. Sometime in 2015, he married jewelry designer Chantel Poynton in Miami, Florida. He can occasionally be seen in Poynton’s Instagram photos, so we do know the couple is together. Gonzalez currently lives in Chicago, where is a well-known face. According to the AbbVie website, Gonzalez is a member of the Commercial Club of Chicago and represents AbbVie on their Civic Committee.
Richard Gonzalez Age
Richard Gonzalez‘s age is unknown.
AbbVie exploits U.S. patents to protect profits
Drugmaker AbbVie exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S. House of Representatives Oversight Committee staff report issued on Tuesday.
AbbVie Inc’s chief executive officer Richard Gonzalez is to testify Tuesday about prices for Humira, which have been increased to $77,000 for a year’s supply, and Imbruvica, which now costs $181,529 for a year’s supply, said the committee, which called Humira “the highest-grossing drug in the world.”
AbbVie partners with Johnson & Johnson subsidiary Janssen Biotech to make Imbruvica, which treats mantle cell lymphoma and other cancers. AbbVie made $16 billion from Humira from U.S. patients in 2020, the report said.
“Documents and information obtained by the committee indicate that AbbVie’s senior executives received larger bonuses by raising the price of Humira, Imbruvica, and other drugs,” the report said, noting that U.S. patients tended to pay more than patients overseas.
The price increases meant that some U.S patients could not afford the medicines and stopped taking them, the report said.
In the case of Humira, the committee found that AbbVie obtained more than 200 patents on the medicine, sometimes called a patent thicket, and used those to prevent generics from entering the market even though the patent on Humira’s active ingredient expired on December 31, 2016.
“AbbVie’s patent strategy is particularly abusive because it seeks to overwhelm potential competitors with the sheer number of patents on Humira regardless of whether individual patients were properly granted under U.S. law. If one patent is invalidated, AbbVie has another patent waiting,” the report said.
AbbVie also reached settlements with competitors who wanted to bring a generic to market, a step that normally brings prices sharply down, which delayed their entry, the report said.